1011244-95-3

Basic information

• Product Name: N-(4-nitro-2-pyridyl)-4-trifluoromethylbenzamide
• Synonyms: N-(4-nitro-2-pyridyl)-4-trifluoromethylbenzamide
• CAS NO: 1011244-95-3
• Molecular Weight: 311.22
• Mol File: 1011244-95-3.mol

Chemical Properties

• CAS DataBase Reference: N-(4-nitro-2-pyridyl)-4-trifluoromethylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-nitro-2-pyridyl)-4-trifluoromethylbenzamide(1011244-95-3)
• EPA Substance Registry System: N-(4-nitro-2-pyridyl)-4-trifluoromethylbenzamide(1011244-95-3)

Safety Data

• Hazardous Substances Data: 1011244-95-3(Hazardous Substances Data)

Upstream product

• 329-15-7 4-trifluoromethyl-phenyl acetyl chloride 
• 23056-36-2 2-chloro-4-nitropyridine 
• 1891-90-3 p-trifluoromethylbenzamide 

Downstream Products

• 1011244-88-4 C₁₃H₁₀F₃N₃O 

Relevant articles and documents

COMPOUND HAVING BENZAMIDE SKELETON AND CYCLOOXYGENASE (COX-1)-SELECTIVE INHIBITORY ACTIVITY

This invention provides a novel COX-1-selective inhibitor. This invention relates to a novel compound represented by the formula below or a salt thereof. This invention also relates to an analgesic agent, an antiinflammatory agent, an antitumor agent, an antiplatelet aggregation agent, and a cyclooxygenase-1-selective inhibitor comprising, as an active ingredient, such compound or salt thereof.

Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor

Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide (18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 ± 0.05 μM, COX-2 IC50 = 210 ± 10 μM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.